- Brief communication
- Open Access
HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept
Journal of Ovarian Research volume 7, Article number: 35 (2014)
Controlled ovarian hyperstimulation (COH) which combining GnRH antagonist co-treatment and GnRH agonist trigger with an additional 1500 IU hCG luteal rescue on day of oocytes retrieval, has become a common tool aiming to reduce severe ovarian hyperstimulation syndrome (OHSS). In the present, proof of concept study, we evaluate whether by deferring the hCG rescue bolus for 3 days, we are still able to rescue the luteal phase.
Patients undergoing the GnRH-antagonist protocol, who were considered at high risk for developing severe OHSS and received GnRH-agonist for final oocyte maturation, were included. For luteal phase support, all patients received an “intense” luteal support. Those who had no signs of early moderate OHSS on day 3 after oocytes retrieval were instructed to inject 1500 IU of HCG bolus (hCG group). Ovarian stimulation characteristics and mid luteal progesterone levels were compared between those who received the HCG bolus and those who did not.
Eleven IVF cycles were evaluated, 5 in the hCG group and 6 in the intense luteal support only group. While no in-between group differences were observed in ovarian stimulation characteristics, significantly higher mid luteal progesterone levels (>127 nmol/L vs 42.1 ± 14.5 nmol/L, respectively) and a non-significant increase in pregnancy rate (40% vs 16.6%, respectively), were observed in those who receive the hCG bolus compared to those who did not.
hCG luteal rescue should be offered 3 days after oocytes retrieval only to those patients with no signs of early moderate OHSS. Further studies are required to elucidate the appropriate regimen of luteal HCG administration in patients undergoing final follicular maturation with GnRH-agonist.
Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovulation induction, almost always presents either after human chorionic gonadotropin (hCG) administration in susceptible patients or during early pregnancy. Despite many years of clinical experience, the pathophysiology of OHSS is poorly understood and there is no reliable test to predict patients who will subsequently develop severe OHSS. Of notice, that while investigating randomized controlled trials that aimed to prevent of severe OHSS, we found that different studies defined high-risk patients by different estradiol (E2) threshold levels, ranging from 1906 to 6000 pg/ml, most used a level of ~3000 pg/ml. Moreover, when all the predictive variables for severe OHSS were combined, the prevalence of severe OHSS in the ostensibly high risk patients was only about 20% an extremely low value for a good predictive measure (false positive-80%).
Furthermore, there are no precise methods to completely prevent severe OHSS, except for withholding the ovulation-inducing trigger of hCG, or replacing hCG with GnRH agonist (GnRHa) to trigger ovulation[3, 4]. However, due to the reported significantly reduced clinical pregnancy and increased first trimester pregnancy loss[5, 6] using the GnRH antagonist controlled ovarian hyperstimulation (COH) protocol with GnRHa trigger, efforts have been made to improve reproductive outcome, by manipulating the luteal phase. The three suggested optional strategies aiming to improve outcome are freeze-all policy; fresh transfer and intensive luteal support; and fresh transfer and low-dose HCG supplementation.
One bolus of 1500 IU hCG 35 h after the triggering bolus of GnRHa (on day of oocytes retrieval) was demonstrated to rescue the luteal phase, resulting in a reproductive outcome comparable with that of HCG triggering, and with no increased risk of OHSS[8, 9]. However, in a recently published retrospective study, Seyhan et al. have challenged the safety of the GnRHa trigger with HCG rescue. They examined whether GnRHa trigger and 1500 IU hCG luteal rescue protocol, completely prevented severe OHSS. Of the 23 patients evaluated, 6 (26%) developed severe OHSS, 5 of whom had severe early OHSS requiring ascites drainage and hospitalization. Figure that is comparable to the aforementioned 20% prevalence of severe OHSS, in high risk patients.
Since early OHSS occurs 3–7 days following hCG trigger for final follicular maturation, it is our policy to withhold the 1500 IU hCG luteal rescue bolus and to follow and re-evaluate these patients for 3 days after oocyte retrieval [day of embryo transfer (ET)] for signs of early moderate OHSS. Only those patients with no signs of early OHSS are instructed to inject 1500 IU of HCG. By deferring the hCG bolus by 3 days (5 days following GnRHa trigger), we believe that we are actually offering the hCG to 80% of the a priori at risk patients (the aforementioned- detection rate c’ 80% false positive), who are not supposed to develop severe early OHSS, while avoiding hCG luteal rescue to the “real” 20-26%[2, 10] patient at risk to develop severe early-OHSS.
The main criticism of the aforementioned protocol, that we aimed to challenge in the present proof of concept study, is whether by deferring the hCG rescue bolus for 3 days, we are still able to rescue the luteal phase, as evident by sufficient mid luteal progesterone levels, without jeopardizing pregnancy rate or increasing the risk for severe OHSS.
We reviewed the computerized files of all consecutive women admitted to our in-vitro fertilization (IVF) unit from August 2013 to December 2013 who reached the oocyte retrieval stage. Only those patients undergoing the multiple-dose GnRH-antagonist protocol, who were considered at high risk of developing severe OHSS, i.e. those with rapidly rising serum E2 levels; peak E2 level in excess of 9175 pmol/L (2,500 pg/mL); and/or the emergence of a large number of intermediate sized follicles and received 0.2 mg triptorelin (Decapeptyl, Ferring, Malmo, Sweden) for final oocyte maturation, were included. The study was approved by our institutional review board (IRB number 0776-13-SMC).
For luteal phase support, all patients received an “intense” luteal support, starting 1 day after oocyte retrieval, that included 4 mg daily E2 valerate per os (Progynova; Schering), combined with either 50 mg progesterone IM (Gestone, Ferring- Lapidot, Israel) daily, 400 mg micronized progesterone vaginal tablets (Endometrin, Ferring-Lapidot, Israel) in two divided doses, or 180 mg micronized progesterone vaginal gel (Crinone® 8%, Merck Serono, Herzelia, Israel) in two divided doses.
Three days after oocyte retrieval (day of ET), patients were evaluated for signs of early moderate OHSS (ultrasonographic signs of ascites as reflected by the appearance of fluid surrounding the uterus/ovaries, and/or hematocrit levels >40% for the degree of haemoconcentration). If signs of early moderate OHSS appeared, one embryo was transferred, and the patient was instructed to continue with the intense luteal support only (Intense support only group). If no early signs of OHSS developed, one embryo was transferred, and the patient was instructed to continue with the intense luteal support and to inject 1500 IU of HCG (hCG group).
According to Engmann’s protocol, serum progesterone levels were measured 4 days after embryo transfer (One week after oocyte retrieval- mid luteal phase), and additional IM progesterone was provided to increase serum progesterone levels if needed.
Data on patient demographics, controlled ovarian hyperstimulation (COH) characteristics and mid luteal progesterone levels were recorded and compared between those who received a bolus of 1500 IU hCG on day of ET (hCG group) and those who did not (Intense support only group).
Results are presented as means ± SD. Differences in variables between the two luteal different luteal supports were statistically analyzed with Student’s t-test and Chi-squared test, as appropriate. A p value of less than 0.05 was considered significant.
Eleven IVF cycles in 11 women were evaluated, 5 in the hCG group (age 31.6 ± 4.6) and 6 in the intense luteal support only group (age 29.8 ± 5.1). The clinical characteristics of the IVF cycles in the two study groups are shown in Table 1.
While no in-between group differences were observed in patients’ body mass index, the length of ovarian stimulation, number of gonadotropin ampoules used, peak E2 and progesterone levels on day of hCG administration, nor in the number of oocytes retrieved (Table 1), mid-luteal progesterone levels were significantly higher in those who receive a 1500 IU hCG bolus, as compared to those who did not (>127 nmol/L vs 42.1 ± 14.5 nmol/L; p < 0.0001, respectively).
Pregnancy was achieved in 2 patients in the hCG group (40%) and one in the intense support only group (16.6%); this difference wasn’t statistically significant. Regarding severe OHSS, no case of severe OHSS was reported among the study groups.
The key to preventing OHSS is experience with ovulation stimulation therapy and recognition of “risk factors” for OHSS. In our practice, normal and high-responder patients undergoing their first IVF attempt are offered the COH with a GnRH antagonist. With this strategy we are able to substitute hCG with the GnRHa to trigger ovulation in those at risk to develop severe OHSS.
In those achieving ≥20 oocytes, the freeze all policy with the subsequent frozen-thawed ET, is usually recommended. However, if less than 20 oocytes are retrieved, patients are instructed to start an intensive luteal support with estradiol and progesterone and are evaluated 3 days after oocyte retrieval for signs of early moderate OHSS. A bolus of 1500 IU hCG is offered only to those with no signs of early moderate OHSS.
In this small series of 11 patients, we demonstrated that by deferring the hCG bolus by 3 days (5 days following GnRHa trigger, instead of day of oocytes retrieval), we are still able to rescue the corpus luteum, with an observed extremely high midluteal progesterone levels and with no cases of severe OHSS. This observation is in accordance with previous studies, in the human as well as the animal model, that demonstrated corpus luteum rescue after three days of LH deprivation[14, 15]. Moreover, in their elegant rhesus monkeys model, Hutchinson and Zeleznik have demonstrated the restoration of gonadotropin secretion following 3-day gonadotropin deprivation period, during the early (days 2–5) and mid (days 8–11) luteal phase (but not in the late ≥ 13 days), that resulted in resumption of progesterone secretion which continued for a period of time which effectively completed the typical lifespan of the corpus luteum.
The mid luteal progesterone levels obtained in our study, in the intense support only group were 42.1 ± 14.5 nmol/L. Figure, that is in the lower range for successful implantation. Moreover, the mid luteal progesterone levels obtained in our study, in patients receiving the hCG luteal bolus 3 days following oocytes retrieval, are comparable to the levels obtained in those receiving the hCG luteal bolus on the day of oocytes retrieval.
Moreover, we believe that by doing so, we are actually offering the hCG to 80% of the a priori at risk patients (the aforementioned- detection rate c’ 80% false positive), who are not supposed to develop severe early OHSS, while avoiding hCG administration to the “real” 20-26%[2, 10] patient at risk to develop severe early-OHSS. Despite a rather limited experience, no case of OHSS has been encountered and a reasonable pregnancy rate was achieved (40%).
Following the study by Seyhan et al., demonstrating an extremely high prevalence of severe OHSS following 1500 IU hCG bolus on day of oocytes retrieval, it seems that those patients triggered by GnRHa for final oocytes maturation, remain with two treatment options: (a) the freeze-all policy- notwithstanding the recent improvement in live birth rates after replacement frozen-thawed vitrified oocytes/embryos, it should be emphasized, that in most centers, there is still a gap in live birth rates between fresh and frozen/thawed cycles (in favor of fresh cycle); and (b) intensive luteal support of estradiol and progesterone- the data regarding the efficacy of this modality are still inconclusive. While comparing our experience with GnRHa trigger before and after modifying our luteal-phase support to the intensive support with E2 and progesterone, we could not demonstrate any differences in peak E2 levels, fertilization rate, number of embryos transferred or implantation and pregnancy rates, between the two luteal support regimens. Moreover, in both groups of luteal support following GnRH-a trigger, implantation and pregnancy rates were lower compared to HCG trigger[6, 18]. Therefore, the search for an optimal luteal support regimen to patients receiving GnRHa trigger should be continued.
In the present study, with its inherent limitation due to the small sample size, we offer a new treatment modality that clearly supports the concept of rescuing the corpus luteum, despite the 3 days delay in hCG administration (3 days following oocytes retrieval). This delay offers the ability to differentiate between those who will benefit from hCG without developing severe OHSS (the 80% false positive) and those who will not. Moreover, the observed reasonable pregnancy rate achieved, with no patient developing severe OHSS are promising, and mandate further large prospective randomized studies.
COH using GnRH antagonist co-treatment and GnRHa trigger, combined with 1500 IU hCG luteal rescue, is a promising protocol, aiming to reduce (rather than eliminating) severe early OHSS, in one hand, and to improve reproductive outcome, in the other. However, according to the present proof of concept study, in the meantime and until further prospective randomized studies elucidating the appropriate dose and timing of HCG administration will appear, we believe that hCG luteal rescue should be offered 3 days after oocytes retrieval only to those patients with no signs of early moderate OHSS.
Controlled ovarian hyperstimulation
Human chorionic gonadotropin
In vitro fertilization
Ovarian hyperstimulation syndrome.
Orvieto R, Ben-Rafael Z: Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998, 5: 110–113. 10.1016/S1071-5576(97)00113-5
Orvieto R, Ben-Rafael Z: Role of intravenous albumin in the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13: 3306–3309. 10.1093/humrep/13.12.3306
Kol S: Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004, 81: 1–5.
Orvieto R: Can we eliminate severe ovarian hyperstimulation syndrome? Hum Reprod 2005, 20: 320–322.
Griesinger G, Diedrich K, Devroey P, Kolibianakis EM: GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006, 12: 159–168.
Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R: Substituting HCG with GnRH agonist to trigger final follicular maturation–a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006, 13: 198–201. 10.1016/S1472-6483(10)60615-3
Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26: 226–230. 10.1016/j.rbmo.2012.11.002
Humaidan P, Bredkjaer HE, Westergaard LG, Andersen CY: 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin- releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010, 93: 847–854. 10.1016/j.fertnstert.2008.12.042
Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM: The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012, 24: 134–141. 10.1016/j.rbmo.2011.11.001
Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH: Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013, 28: 2522–2528. 10.1093/humrep/det124
The Practice Committee of the American Society for Reproductive Medicine (ASRM): Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90: S188-S193.
Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C: The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 2008, 89: 84–91. 10.1016/j.fertnstert.2007.02.002
Orvieto R: Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. J Ovarian Res 2013, 6: 77. 10.1186/1757-2215-6-77
Weissman A, Loumaye E, Shoham Z: Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Hum Reprod 1996, 11: 943–949. 10.1093/oxfordjournals.humrep.a019329
Hutchison JS, Zeleznik AJ: The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. Endocrinology 1985, 117: 1043–1049. 10.1210/endo-117-3-1043
Hull MG, Savage PE, Bromham DR, Ismail AA, Morris AF: The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (“ovulation”) derived form treated and untreated conception cycles. Fertil Steril 1982, 37: 355–360.
Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P: Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2013, 100: 742–747. 10.1016/j.fertnstert.2013.05.028
Orvieto R: Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012, 24: 680–681. 10.1016/j.rbmo.2012.03.005
The authors declare that they have no competing interests.
JH- Participated in the clinical management and collected the data, performed the statistical evaluations, assisted in writing the paper and edited it in all its revisions. AK- Participated in the clinical management and edited the paper in all its revisions. RM- Participated in the clinical management and edited the paper in all its revisions. SD- Participated in the clinical management and edited the paper in all its revisions. AH- Participated in the clinical management and edited the paper in all its revisions. GY- Participated in the clinical management and edited the paper in all its revisions. RO- The principal investigator, designed the study, participated in the clinical management, performed the statistical evaluations, assisted in writing the paper and edited it in all its revisions. All authors read and approved the final manuscript.